Gene Solutions And Element Biosciences Enter Strategic Collaboration To Advance Next-generation Sequencing Ngs Technology Globally
Gene Solutions , a leading multinational biotech company specializing in advanced genetic testing, and Element Biosciences , a company democratizing access to advanced life science solutions, have entered into a strategic collaboration. The collaboration was formalized with the signing of a Memorandum of Understanding MoU during Element Biosciences visit to Gene Solutions laboratory.
This collaboration aims to create significant synergies by combining Element Biosciences groundbreaking sequencing platforms with Gene Solutions innovative technologies in genetic solutions. Element Biosciences has rapidly emerged as a leading innovator in the next generation sequencing NGS field, delivering novel solutions that provide exceptional performance and flexibility for researchers. Gene Solutions, with its comprehensive portfolio of genetic tests, leveraging NGS and artificial intelligence, has reached over 4,500 hospitals and clinics in eight Asian countries and is actively expanding its global footprint.
Equity in Reproductive Health: Accessibility of Non-invasive Prenatal Testing NIPT
NIPT is one of the most well-known clinical applications of NGS technology worldwide. The test screens for genomic abnormalities in cell-free DNA fragments released from the placenta into the mothers blood 1 and is recommended for all pregnant women from 9-10 weeks of gestation. Over the past eight years, Gene Solutions has developed a strong portfolio of NIPT trademarked as triSure TM and a comprehensive ecosystem for reproductive health from pre-birth to newborn and postnatal diagnosis. The company uniquely integrates recessive diseases and dominant single-gene disorders screening in a single workflow with NIPT, leveraging its AI platform and optimized lab protocols. Currently, Gene Solutions is researching the incorporation of pregnancy complications prediction into the NIPT test.
The NIPT market was valued at USD 5.20 billion in 2022 and is projected to grow to USD 19.09 billion by 2030 2 . Gene Solutions seeks to leverage Elements accessible and affordable research solutions to support its aim to bring safe, accurate, and non-invasive screening tools to all pregnant women.